Bristol Myers, Ono sue Amgen to block Opdivo biosimilar
Bristol Myers Squibb and Ono Pharmaceutical sued Amgen in Delaware federal court seeking to block Amgen’s proposed U.S. biosimilar of Opdivo.
S. biosimilar of their blockbuster cancer immunotherapy drug Opdivo. The case is Bristol-Myers Squibb Co. v.
S. Dist…